Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

17.19
+1.177.30%
Post-market: 17.190.00000.00%19:30 EDT
Volume:353.91K
Turnover:6.02M
Market Cap:646.71M
PE:-9.99
High:17.35
Open:16.18
Low:15.88
Close:16.02
52wk High:17.35
52wk Low:8.60
Shares:37.62M
Float Shares:27.82M
Volume Ratio:0.42
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:2.70
PE(LYR):-7.92

Loading ...

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Hold from Morgan Stanley

TIPRANKS
·
Aug 17

Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating

MT Newswires Live
·
Aug 17

Contineum Therapeutics CEO Carmine Stengone Disposes of Shares Worth $40,029

Reuters
·
Aug 04

Contineum Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 03

Buy Rating Reaffirmed on Contineum Therapeutics with Unchanged $26 Price Target, Backed by Advancing IPF and MDD Pipelines

TIPRANKS
·
Aug 01

Contineum Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 01

RBC Lifts Price Target on Contineum Therapeutics to $23 From $22, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 31

Contineum Therapeutics Inc Expected to Post a Loss of 42 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Contineum Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate

Benzinga Earnings
·
Jul 31

Contineum Therapeutics Inc Q2 Net Loss Per Share $0.40

THOMSON REUTERS
·
Jul 31

Contineum Therapeutics - Implements Workforce Reduction Including Chief Scientific Officer Daniel Lorrain

THOMSON REUTERS
·
Jul 31

Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth

Simply Wall St.
·
Jul 17

Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership

TIPRANKS
·
Jul 14

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 16,640 in Common Shares

Reuters
·
Jul 11

Contineum Therapeutics CEO Carmine N. Stengone Disposes of 2,500 Shares for $40,000

Reuters
·
Jul 09

Contineum Therapeutics CSO Daniel S. Lorrain Disposes of USD 556,791 Common Shares

Reuters
·
Jul 03

Contineum Therapeutics CEO Carmine Stengone Sells 10,000 Common Shares for $160,080

Reuters
·
Jul 02

Contineum publishes manuscript on PIPE-791 in Journal of Medicinal Chemistry

TIPRANKS
·
Jul 01

Contineum Launches Global Phase 2 Trial of Pipe-791 in Idiopathic Pulmonary Fibrosis Patients

Reuters
·
Jul 01